PharmaUracil 500mg IV Inj

Oncologists give this chemotherapy alone or in combination regimens through a vein.

PharmaUracil 500mg IV Injection Ingredients and Usage

PharmaUracil 500mg IV Injection contains fluorouracil, a pyrimidine antimetabolite used in chemotherapy. An antimetabolite is a drug that mimics a natural building block of DNA to disrupt cancer cell growth. Oncologists use PharmaUracil for several solid tumours.

PharmaUracil 500mg IV Injection treats colorectal cancer as the backbone of regimens like FOLFOX and FOLFIRI. It also treats breast, stomach, pancreatic, and oesophageal cancer. Doctors often combine PharmaUracil with leucovorin, oxaliplatin, or irinotecan.

How Does PharmaUracil 500mg IV Injection Work?

PharmaUracil 500mg IV Injection converts inside the cell into active metabolites that block DNA and RNA synthesis. Its main metabolite FdUMP inhibits thymidylate synthase, the enzyme that builds thymidine for new DNA. This blockade starves the cancer cell of a key DNA building block.

A second metabolite, FUTP, slots into RNA and disrupts protein synthesis and cell function. Together these actions damage DNA and impair RNA in rapidly dividing cancer cells. The cell then dies through apoptosis, halting tumour growth.

PharmaUracil 500mg IV Injection Side Effects

PharmaUracil 500mg IV Injection causes side effects common to antimetabolite chemotherapy. Mouth sores, low blood counts, and digestive problems are the most frequent effects.

• Mucositis and mouth sores (stomatitis)

• Diarrhoea, nausea, and vomiting

• Myelosuppression (neutropenia, thrombocytopenia, anaemia)

• Hand foot syndrome (palmar plantar erythrodysaesthesia)

• Fatigue and weakness

• Hair loss (alopecia)

• Skin darkening and nail changes

• Higher risk of infection

Warnings

• PharmaUracil is dangerous in patients with dihydropyrimidine dehydrogenase (DPD) deficiency. DPD is the enzyme that clears fluorouracil, and its absence causes severe, sometimes fatal toxicity.

• PharmaUracil can cause cardiotoxicity, including angina, heart attack, arrhythmia, and heart failure. Doctors stop treatment promptly at the first sign of cardiac symptoms.

• PharmaUracil causes severe bone marrow suppression, raising the risk of infection and bleeding. It is contraindicated in patients with existing severe bone marrow depression.

• PharmaUracil interacts dangerously with the antiviral sorivudine and related drugs. This combination blocks fluorouracil breakdown and can cause fatal toxicity.

• PharmaUracil causes embryo fetal harm and is contraindicated in pregnancy and breastfeeding. Both male and female patients must use effective contraception during treatment.

PharmaUracil 500mg IV Injection Storage Conditions

Store PharmaUracil 500mg IV Injection at room temperature between 15°C and 30°C, protected from light in its original carton. Do not refrigerate or freeze the vial, since cold can cause the solution to form a precipitate. Keep PharmaUracil out of the reach of children, and let only trained hospital staff handle and administer it.